Is CELC a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Gedatolisib FDA decision and launch, with revenue (ttm) at ~$0 (pre-revenue, clinical-stage). The bear case rests on celcuity is a pre-revenue, essentially single-asset company, so a delay or rejection at the PDUFA date, a label narrower than hoped, or disappointing later cohort data could sharply reduce the value the market assigns. Analysts covering it are spread from $148.00 to $178.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Celcuity is a pre-revenue, essentially single-asset company, so a delay or rejection at the PDUFA date, a label narrower than hoped, or disappointing later cohort data could sharply reduce the value the market assigns. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $148.00, +84.1% from the $80.41 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Gedatolisib FDA decision and launch. The July 17, 2026 PDUFA date for the HR+/HER2-/PIK3CA wild-type indication is the single largest catalyst. The most optimistic analyst target on CELC is $178.00, +121.4% from the $80.41 price. That figure is only reachable if this thesis works close to its best case.

Celcuity is a pre-revenue, essentially single-asset company, so a delay or rejection at the PDUFA date, a label narrower than hoped, or disappointing later cohort data could sharply reduce the value the market assigns. It posted a net loss of roughly $52.8 million in the first quarter of 2026 and funds operations from cash plus a debt facility, so additional equity or debt financing (and potential dilution) is a live risk if a launch takes longer or costs more than planned. Even with approval, commercial uptake faces entrenched and newly approved competitors, payer and pricing pressure, and the operational challenge of a first launch. The stock has been volatile and can gap on single events, which is characteristic of clinical-stage biotech rather than a defect specific to this name. The most pessimistic published target is $148.00, +84.1% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Celcuity Inc.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Gedatolisib FDA decision and launch) stalling in the reported numbers rather than in the narrative, the risk above (celcuity is a pre-revenue, essentially single-asset company, so a delay or rejection at the PDUFA date, a label narrower than hoped, or disappointing later cohort data could sharply reduce the value the market assigns) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Celcuity is a clinical-stage biotechnology company developing targeted cancer therapies. Its lead drug, gedatolisib, is a pan-PI3K/AKT/mTOR inhibitor being developed for HR+/HER2- advanced breast cancer, and the company also runs diagnostic and functional-testing work supporting its programs.

No. Celcuity is pre-revenue and reported a net loss of roughly $52.8 million in the first quarter of 2026. It funds heavy research spending from cash, short-term investments, and a debt facility rather than from product sales.

Gedatolisib is Celcuity's lead drug candidate, an intravenously administered inhibitor that blocks all four class I PI3K isoforms plus mTORC1 and mTORC2. The design aims to suppress the whole pathway at once and reduce the adaptive resistance that single-target drugs can trigger.